Dermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the proposed maximum price is estimated at $97.75 million but this is really just a placeholder.
Source: Thinkstock
The underwriters for this offering are Leerink Partners, Cowen, Needham, and Guggenheim.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The management team has extensive experience in product development and commercialization, having served in leadership roles at several leading dermatology companies.
Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Dermira believes can be successful in the dermatology marketplace. The company has a portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: Cimzia (certolizumab pegol), for the treatment of moderate-to-severe plaque psoriasis; DRM04, for the treatment of hyperhidrosis, or excessive sweating; and DRM01, for the treatment of acne.
The company is currently focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as psoriasis, hyperhidrosis and acne. These diseases impact millions of people worldwide and can have significant, multidimensional effects on patients’ quality of life, including their physical, functional and emotional well-being.
Finally, Dermira currently intends to use the net proceeds from this offering for external research and development expenses associated with the development of Cimzia, DRM04 and DRM01 product candidates, with the balance primarily used to fund internal research and development expenses associated with all of the product candidates, working capital, capital expenditures and other general corporate purposes.
ALSO READ: How The Biggest Biotech IPO Did In Its Debut
Shares of Dermira closed Tuesday up 0.2% at $24.37 on a 52-week trading range of $12.68 to $25.24. The stock has a consensus analyst price target of $24.75.
ALERT: Take This Retirement Quiz Now (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
